A device aimed at enabling neurosurgeons and other physicians to perform noninvasive blood-based biopsies in adults with brain tumors has received Food and Drug Administration (FDA) “Breakthrough Device” designation. The device includes technology from Washington University in St. Louis and developed by Cordance Medical Inc., a medical device company in Mountain View, Calif.
The designation is aimed at providing patients and health-care providers with timely access to novel medical devices by expediting the review process needed to bring technology toward market approval.
The FDA distinction applies to devices that have undergone rigorous review and show exceptional promise of improved treatment or the ability to diagnose life-threatening or debilitating diseases. The technology was co-invented by Eric C. Leuthardt, MD, the Shi Hui Huang Professor of Neurosurgery at Washington University School of Medicine, and by Hong Chen, PhD, an associate professor of biomedical engineering at the university’s McKelvey School of Engineering and of neurosurgery at the School of Medicine.
Washington University recently licensed the technology to Cordance Medical. Leuthardt and Chen serve as advisers and shareholders of Cordance Medical, which is involved in commercializing the technology.
The device — called NeuroAccess — is portable and noninvasive, and it allows physicians to avoid high-risk brain surgery to obtain blood-based liquid biopsies of patients who have known or suspected brain tumors. The device uses sonobiopsy, a technique that targets the blood-brain barrier, a protective, semi-permeable membrane that prevents harmful substances in the blood from contaminating sensitive tissue in the brain. The interaction of ultrasound and microbubbles causes the blood-brain barrier to open temporarily so RNA, DNA and proteins from the brain can diffuse into the blood.
“The sonobiopsy approach is a revolution in brain diagnostics,” said Leuthardt, also a professor of biomedical engineering, of mechanical engineering and of neuroscience. “Just as magnetic resonance imaging (MRI) transformed how we look at the anatomy of the human brain, sonobiopsy will transform how we examine the brain on a molecular level. Essentially, we’re doing a brain biopsy without the high risks of brain surgery.”
The researchers published a study in September, in the journal NPJ Precision Oncology, that found sonobiopsy was feasible and safe for use in people.
“The breakthrough designation is the success of a team that spans numerous disciplines ranging from medicine, engineering, genetics, neuroscience and entrepreneurship to bring this concept from a very basic scientific model to an ongoing clinical trial,” Leuthardt said. “This is a triumph of collaboration.”
Said Chen, also a professor of radiation oncology and of radiology: “Sonobiopsy is poised to open doors to diagnose brain diseases in which surgical biopsies are often not an option. The technology presents new opportunities in the diagnosis of neurodevelopmental, neurodegenerative and psychiatric disorders.”
Leuthardt is the director and Chen is a member of the Division of Neurotechnology in the Department of Neurosurgery, which focuses on multidisciplinary research to create innovative engineered solutions that can be translated to patients with neurologic diseases. Washington University owns a patent on the sonobiopsy technology.
About Washington University School of Medicine
WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,800 faculty. Its National Institutes of Health (NIH) research funding portfolio is the third largest among U.S. medical schools, has grown 52% in the last six years, and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,800 faculty physicians practicing at 65 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children’s hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.